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Abstract
Background: Novel therapeutic agents recently introduced for the treatment of cancer have several unusual side
effects. An increased incidence of renal cystic lesions, often with features concerning for malignancy or infection,
has been reported in patients with anaplastic lymphoma kinase (ALK) - rearranged advanced non-small cell lung
cancer (NSCLC) treated with Crizotinib. Many of these lesions undergo spontaneous resolution despite developing
complex features on imaging. We assess the incidence and patterns of evolution of Crizotinib Associated Renal
Cysts [CARCs] at our institute and provide histopathology correlation of their benign nature.
Methods: A retrospective analysis of renal lesions in computerised tomography (CT) scans of 35 patients with advanced
ALK-rearranged NSCLC who had been prescribed crizotinib at our institution was performed by three radiologists, who
analysed the evolution of these lesions, particularly for pre-defined significant and complex changes.
Results: Of 26 patients eligible for this analysis, 4 (15%) had cysts at baseline that remained stable on crizotinib
treatment while 11(42%) developed significant change in 28 renal cysts. Commonest pattern of cyst evolution
was enlargement from baseline followed by spontaneous regression (17/28 lesions) while other patterns noted
were stable lesions, regression from baseline and ongoing enlargement. The median maximum size reached was
23 mm (range 9 – 67 mm) after a median of 178 days (160 to 1342) on crizotinib. Complex change occurred in
12 cysts, in 7/26 (27%) patients and within 60 days of starting Crizotinib in 10 cysts. Imaging features were falsely
concerning for malignancy or abscess in 4/26 patients.
Conclusion: Most CARCs resolve spontaneously, or have a benign evolution despite enlargement and other features
concerning for malignancy or infection on imaging. This unusual manifestation of chemotherapy should be
recognised, particularly by radiologists, so that inappropriate treatment decisions are avoided.
Keywords: Crizotinib, Renal cyst, Spontaneous resolution, CT, Non-small cell lung cancer, Anaplastic
lymphoma kinase
Background
Anaplastic Lymphoma Kinase (ALK) gene rearrange-
ments were first identified in NSCLC in 2007 [1] and
subsequently found to be present in approximately 4%
of patients with NSCLC [2]. Crizotinib (Xalkori, Pfizer;
PF0234066), a tyrosine kinase inhibitor with efficacy
against ALK [3], c-MET [4] and ROS1 [5] kinase, has
demonstrated superior efficacy over chemotherapy in
the first line systemic treatment of advanced ALK-
rearranged NSCLC and represents standard of care for
this patient population [6]. With observed median pro-
gression free survival (PFS) of 10.9 months and further
benefit gained in some cases by continuing crizotinib be-
yond progression [7], many patients remain on this
treatment for years. CT scans performed regularly to
monitor disease response also reveal crizotinib related
toxicities. Complex renal cysts were reported as a rare
complication of crizotinib therapy during clinical trials,
initially with an incidence of 4% [8], and more recently,
of up to 22% [9, 10]. These cysts have even been noted
to invade extrarenal spaces and in a minority, these
complex masses can be symptomatic with flank pain
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[10]. Complex renal lesions arising while on crizotinib
therapy can regress without intervention, regardless of
whether crizotinib therapy is ceased [9, 11]. We per-
formed a retrospective analysis of the incidence and pat-
tern of evolution of all renal lesions in CT in lung
cancer patients who received crizotinib at our centre.
Methods
Patients with advanced ALK-rearranged NSCLC who
had been prescribed crizotinib at our institution were
identified via the institutional Thoracic Malignancies
Cohort database that commenced data collection in July
2012. The cohort included patients on clinical trial and
those receiving crizotinib via a special access scheme
with Pfizer. The collection of data for our retrospective
study was conducted under an ethics approved protocol:
the Peter MacCallum Cancer Centre thoracic malignan-
cies cohort study (Peter MacCallum Cancer Centre
Human Research Ethics Committee project 11/88) to
which patients gave consent to allowing their clinical
data and tissue biopsies to be used for future research.
To be included in our study, patients needed to have
been recruited to the cohort prior to July 2014, have
been on crizotinib therapy for at least 2 months, had
intravenous contrast enhanced Computed Tomography
(IVCECT) prior to commencement of crizotinib therapy
and regular follow up IVCECTs, with all scans covering
the renal region completely. Patients whose baseline or
most follow up CT scans were suboptimal (from lack of
IV contrast or movement artefacts affecting assessment
of kidneys), those who had proven renal metastases at
baseline and those who had interventional procedures
on kidneys other than biopsy while on crizotinib were
excluded from this analysis. Patients whose baseline scan
was 18FDG PET/CT scan without IV contrast were in-
cluded in our study only if the CT component of the
PET scan unequivocally showed the renal lesion identi-
fied in the subsequent IVCECT. The presence, size,
number and morphology of all renal lesions were ana-
lysed at baseline and in all CT scans performed while on
crizotinib by three radiologists [DJ, KM and BP], obtain-
ing consensus regarding lesion description and morph-
ology as described later. Whilst the vast majority of
scans were performed in-house, with sub-millimetre
axial helical CT acquisition [Siemens Definition AS+,
Siemens AG, Germany], images of the renal region avail-
able for review on the image archiving system were the
standard 5 mm thick axial and coronal reconstructions.
Renal lesions were included if they were at least 4 mm
and were able to be assessed in at least two consecutive
scans. They were considered as cysts if they were well
defined and showed fluid attenuation [less than 20 HU].
As the CT scans were performed to stage lung cancer,
the renal region was covered in most cases only in the
portal venous phase, technically not permitting accurate
classification of renal lesions by Bosniak criteria. Renal
cysts were considered complex if they demonstrated
poorly defined margins, density higher than simple fluid
(for lesions larger than 1 cm), septae or solid or mixed
cystic and solid appearance. Significant renal cystic
change was defined as an increase or decrease in size of
the cyst by more than 3 mm, or development of any of
the complex features mentioned above. Additional pa-
tient, malignancy and treatment related information was
extracted from the prospective cohort database and col-
lected on retrospective review of clinical records.
Results
Thirty five patients with NSCLC received crizotinib ther-
apy at our centre in the defined 4 year period. Nine of
these patients were excluded from our study; 6 due to
suboptimal imaging, 1 due to biopsy proven renal metas-
tases on baseline scan, 1 due to nephrostomy while on
treatment and 1 due to an insufficient period of treat-
ment with crizotinib. Of the remaining 26 patients, 10
(38%) remained on crizotinib at our data collection cut-
off and only one patient discontinued therapy due to
complex renal cyst formation. Patient, tumour and treat-
ment characteristics are presented in Table 1.
Eleven of 26 (42%) patients had no cysts as per our
criteria at baseline or in the study period [8 had no cysts
at all; 3 had cysts smaller than 4 mm]. 4 of 26 (15%) had
cysts at baseline that remained stable on crizotinib treat-
ment. 1 of these patients had a cyst that was complex
(due to high density content) at baseline. The remaining
11 (42%) developed a significant change in renal cysts as
per our study criteria in a total of 28 renal lesions.
Table 1 Patient, tumour and treatment characteristics (N = 26)
Age (median, range) 52 (34-66)
Sex (Female) 42%
Ethnicity Asian 31%, Caucasian 69%
Smoking status Never 58%, light (<10-pyHx) 15%,
heavy (>10pyHx) 27%
Diagnosis Stage IV 96%, confirmed
Adenocarcinoma 96%. ALK FISH
rearranged: 92%.




Crizotinib as line of treatment 1st 34%, 2nd 31%, 3rd 27%,
4th 0%, 5th 8%.
Best radiological response PD 0%, SD 12%, PR 73%, CR 15%
PD progressive disease, SD stable disease, PR partial response, CR
complete response
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Radiologically significant renal cyst changes
Eight of the 11 patients with significant change in the
renal lesions had more than 1 lesion, with as many as 5
in 1 patient. The evolution in size of the 28 cysts varied
greatly between and within patients as demonstrated in
Table 2 and Fig. 1. Interestingly, all patients who had
more than one cyst showed a mixed pattern of cyst evo-
lution Among them, these 11 patients had 20 cysts at
baseline that subsequently showed significant changes; 8
new CARCs were noted in four patients during the
study period.
Size
Nineteen of the 28 lesions in these 11 patients had a sig-
nificant growth of renal cysts by our definition (Table 2).
In these growing lesions, the median maximum size
reached was 23 mm (range 9 – 67 mm) after a median of
178 days (160 to 1342) on crizotinib. The median max-
imum increase in cyst size from baseline was 10 mm
(range 4-52 mm) which corresponded to a median per-
centage increase in size of 63% (range 40 to 347). 95% (18/
19) grew by more than 50%. The median rate of growth
was 18 mm/year.
The most common pattern of evolution of the renal
cysts was enlargement from baseline followed by spon-
taneous regression (17/28 lesions), either partially (13/17
lesions) or completely (4/17 lesions), with residual mild
cortical scarring (Fig. 2). New cysts developed in 4 pa-
tients; 3 of these patients had other pre-existing lesions
that were enlarging when new lesions arose. Although
de novo cysts did arise and significantly evolve, all 11 pa-
tients in whom significant renal cystic change occurred
had at least 1 renal cyst at baseline. Eleven other patients
without any cysts at baseline did not go on to develop
renal cysts.
Less common patterns of evolution of renal lesions
noted concurrently in patients with significantly changing
cysts were stable cysts (7 lesions in 5 patients), regression
of cysts existing at baseline (2 lesions in 2 patients; 1 with
partial and the other with complete regression), and on-
going enlargement. 2 patients showed ongoing enlarge-
ment of renal cysts at the end of our study period. 1
patient had a cyst that continued to enlarge at data cut-
off, from 6 mm to 27 mm (Fig. 3) over 45 months on
treatment. A new cyst that developed in another patient
2 months after start of crizotinib also continued to en-
large, reaching 49 mm on imaging 2 months later, shortly
before the patient died due to disease progression.
Complexity
The development of complex features, as defined above,
apart from simple changes in size, occurred in 12 cysts,
affecting 7/26 (27%) patients overall (Table 3). The me-
dian (range) time on crizotinib to development of initial
and most complex changes were 172 (0 to 380) days and
199 (130 to 380) days respectively. In 10 cysts, the most
complex changes were seen within 60 days of onset. The
earliest development of new complex features was seen
after 51 days on crizotinib. Bosniak classification was
not applied but development of lesions with septations
or mixed cystic and solid appearances were noted to be
the two most common patterns of complex change in
CARCs. Psoas muscle or abdominal wall invasion was
seen in 2 lesions in one patient (Table 3). In 4/26 pa-
tients, the imaging features of the lesions were concern-
ing for malignant change or abscess and 2 of these
Table 2 Cyst evolution in patients with significant renal cystic change (N = 11): PR - partial regression
















1 280 2 Y 0 1 1
2 1344 1 N 0 1
3 678 2 Y 0 1 1; CR
4 126 5 Y 4 (+4) 1
5 686 4 Y 0 1 2 1; PR
6 150 3 Y 0 1 2
7 547 1 N 0 1
8 1109 4 Y 1 2 (+1) 1
9 160 2 Y 1 (1) 1
10 1477 1 N 0 1
11 1456 3 Y 2 1(+2)
Median age 48 years;
45% F; 64% Asian
Median 678 28 4/11 patients 13/28 cysts 4/28 cysts 2/28 cysts 7/28 cysts 2/28 cysts
CR complete regression, (+) new lesion
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patients (Figs. 4 and 5) developed flank pain. Subsequent
CT guided biopsy and diagnostic aspiration of few milli-
litres of cyst contents in these 2 patients (from psoas le-
sion in one patient and from the renal lesion in the
other) revealed benign histology, with both samples
showing xanthogranulomatous inflammation. The biop-
sies showed degenerate cellular debris, fibrosis and a
mixed inflammatory infiltrate, including lymphocytes,
neutrophils and numerous macrophages, many with
foamy cytoplasm. No residual cyst wall was identified, no
micro-organisms were seen or cultured, and no malignant
cells were present. Both patients had resolution of cystic
changes, one after cessation of crizotinib (Fig. 4) and the
other despite ongoing treatment with crizotinib (Fig. 5).
Correlation between evolution of renal cysts and disease
response/ renal function
Of the 11 patients with significant renal cystic change, 2
had progressive disease and 9 had continued response (2
complete, 7 partial) at the time of maximum cystic
change. There was no apparent association between cyst
evolution and renal impairment. The median (range)
serum Creatinine was 78 (57 to 92) μmol/L at com-
mencement of Crizotinib and 79 (61 to 106) μmol/L at
the time of maximum cystic change. Urinalysis was per-
formed on 5 patients at the time of maximum cystic
change and all results were normal.
Discussion
In the general population, renal cysts are thought to be
acquired lesions that evolve from diverticula in distal
convoluted and collecting renal tubules [12]. The preva-
lence of CT detected simple cysts increases with age and
has been estimated at 27.5% in 40-60 year olds; 49% in
those 60-80 years and 60.6% in those above 80 [13]. The
natural history of simple renal cysts is to slowly en-
large, with reported average size increase and rate of
enlargement of 1.6 mm and 3.9% per year,
Fig. 1 Evolution of CARCs in our cohort: Graph demonstrating evolution in size of the largest CARC in mm (Y-axis) versus days on crizotinib
(X-axis) in 11 patients
Fig. 2 Pattern of evolution of one of the CARCs in patient 1: Axial CT images of the left kidney show enlargement of a 9 mm cyst in patient 1
that was present at baseline in February 2013 (a) to 17 mm in September 2013 (b) followed by spontaneous resolution leaving a cortical scar in
January 2014 (c) with ongoing crizotinib therapy
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respectively [14]. Thus, the prevalence of renal cysts
(58%) in our patient cohort (median age 52 years) at
baseline was higher than expected.
Within the limits of our small sample size, the rate of
growth of renal cysts in our patients on crizotinib was
noted to exceed that expected in the natural history of
simple cyst evolution. A potential limitation of our study
is the lack of comparison in evolution of renal cysts in
ALK-rearranged NSCLC. There was not an apparent de-
velopment of renal cysts in ALK-rearranged NSCLC pa-
tients who received chemotherapy on trial [10] but
larger population studies would be difficult to undertake
given the efficacy and availability of crizotinib in this
population moving forward.
Using predefined criteria for significant change in size
and complexity of renal cysts, our study confirms the
previously reported increase in size and complexity of
renal cysts after commencing crizotinib. In this report
we describe the highest incidence of radiologically sig-
nificant renal cyst change (42%) and new complex fea-
tures (27%) to date. Our definitions of significant renal
cystic change differ only slightly from previous reports.
Lin et al. [9] reported a 22% incidence of significant
renal cystic change as defined by new renal cysts more
than 4 mm in size, enlargement or regression of previ-
ous cysts by more than 4 mm or development of compli-
cated renal cysts (Bosniak IIF or higher). Schnell et al.
[10] report 2% of cysts to significantly enlarge defined as
an increase by more than 50%, however this rate was de-
termined based on cyst detection at the 6 month scan.
Our cohort demographics were similar to previous re-
ports in terms of smoking status, adenocarcinoma and
median age, reflecting the expected characteristics of pa-
tients with NSCLC harbouring ALK gene rearrangement.
Fig. 3 Ongoing enlargement of CARC: Coronal CT images show continued slow enlargement of a right lower pole renal cyst, 6 mm at baseline
in July 2010 in patient 10 on crizotinib over 45 months from start of treatment at time points August 2010 (a), April 2013 (b) and May 2014 (c)





Number of cysts demonstrating:
Enlargement New hyper-
density








1 #1 1 1 1 - - - - -
2 #4 5 5 - 4 5 - 2 2
3 #5 1 1 1 - - 1 - -
4 #8 1 1 1 1 - - 1 -
5 #9 1 1 1 1 - - -
6 #10 1 1 - 1 1 - - -
7 #11 2 2 - 1 1 - 1 -
Total 7 12 12 4 7 8 1 4 2
Complex change@: does not include lesions with change only in size
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We have demonstrated a variety in the pattern of cyst
evolution, even within the same kidney. The clearly
dominant pattern of evolution of CARCs in our study
was, as reported in literature, asymptomatic cysts that
enlarged and spontaneously regressed without discon-
tinuation of crizotinib or need for intervention. It did
appear that cysts regressed slightly faster in our single
case in whom crizotinib was discontinued (Fig. 4) than
in those who continued on treatment (Fig. 5). In
addition to this dominant pattern of evolution of renal
cysts, we also noted three other previously unreported
patterns, namely stability of cysts detected at baseline,
regression of lesions from baseline and progressive en-
largement of lesions from baseline. The pattern of on-
going cyst enlargement we noted, however, likely
represents only a rarer pattern of very slow spontaneous
regression, as one of the 2 patients in whom this pattern
was observed started showing spontaneous regression of
his CARC 16 months after the end of our study period
and the other patient died due to disease progression
after 5 months of crizotinib therapy.
Renal cysts can be graded using the Bosniak classification
system that scores the cyst complexity from I-IV [15].
Higher grades have a higher likelihood of malignancy and
current recommendations for Bosniak class III/IV renal
cysts include surgical resection [16]. Accurate assessment
of cyst morphology and enhancement characteristics re-
quires both non-enhanced and IV contrast enhanced scans
to be performed [17]. CT scans in our study were routinely
performed only in the portal venous phase. This limitation
of our study was addressed by applying commonly ac-
cepted features of complexity in renal cysts to the portal
venous phase scans. The two commonest complex features
we noted in CARCs were the development of multiple sep-
tations and a mixed cystic and solid appearance.
The differential of renal cysts demonstrating complex
features in a patient with NSCLC includes infection,
renal metastases and primary renal malignancy. In two
of our patients with CARCs, the imaging and clinical
features were concerning enough to warrant a biopsy. In
both, CT guided aspiration and biopsy revealed benign
histology of xanthogranulomatous inflammation with
Fig. 4 Resolution of CARC upon ceasing crizotinib in patient 4: Coronal CT demonstrating left renal cysts with perinephric and psoas invasion (a).
Histology of CT guided biopsy from left psoas lesion revealed xanthogranulomatous inflammation (Haematoxylin and eosin, original magnification
x200) (b). Coronal CT demonstrating resolving cystic changes after discontinuing crizotinib (c). Graph: Maximum renal cyst diameter (mm) versus days
on crizotinib, demonstrating evolution of five cysts in this patient (d)
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negative bacterial culture and no malignant cells evident.
Several recent case reports have also documented benign
pathology upon aspiration of complex cysts in patients
with NSCLC treated with Crizotinib [18–20]. Prior
knowledge and prompt recognition of CARCs may help
avoid unnecessary biopsy/drainage and suboptimal treat-
ment of lung cancer.
While reported regression of the CARCs may have
been hastened by drainage [18–20], our experience sug-
gests that these lesions spontaneously resolve.
Percutaneous drainage may be warranted to relieve
symptoms of enlarging cysts or to investigate for infection
if concerning clinical features such as fever are apparent.
We propose that, when found incidentally on imaging,
CARCs could simply be observed without intervention or
cessation of crizotinib.
The pathogenesis of renal cyst development due to cri-
zotinib is unknown. In response to acquired resistance
to crizotinib, several more potent next generation ALK
inhibitors have been developed and are now used in the
clinical setting [21] Renal cysts have not been reported
as a complication of these more specific ALK directed
therapies indicating that cystogenesis may be driven by
inhibition of other molecules targeted by crizotinib.
Fig. 5 Resolution of CARCs without ceasing crizotinib in patient 11: Baseline scan demonstrated an 8 mm cyst in the right kidney (a). Enlarging
right renal cyst with no complex features and the new left renal cyst with mixed solid and cystic areas and poorly defined margins (b). A new
right upper pole cyst with septations is not shown. CT guided aspiration/ biopsy of the left renal lesion revealed xanthogranulomatous inflammation
(Haematoxylin and eosin, original magnification x200) (c). All three cysts spontaneously resolved with ongoing Crizotinib therapy (d). Graph: Maximum
renal cyst diameter (mm) versus days on crizotinib, demonstrating evolution of the three cysts in this patient (e)
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Crizotinib was initially developed as a c-MET inhibitor.
The ligand to c-MET, hepatocyte growth factor (HGF) is
thought to mediate human renal cyst formation [22].
Thus it would be paradoxical that inhibition of c-MET
by crizotinib would drive cyst formation unless an un-
identified feedback mechanism increased levels of HGF
to drive cyst formation via another target.
Pre-clinical studies investigating an apparent link be-
tween testosterone and polycystic kidney disease have
conflicting results [23, 24] and although crizotinib has
been shown to reduce testosterone levels [25] we were
not able to investigate testosterone levels in our retro-
spective analysis. Although small numbers don’t allow
statistical certainty, it did appear that renal cysts devel-
oped in a higher proportion of Asian patients as previ-
ously reported [9].
Conclusions
In summary, development of complex renal cysts is not
an uncommon side effect of treatment with crizotinib.
Cysts are typically benign, asymptomatic and resolve
spontaneously on continued crizotinib therapy. As the
use of crizotinib becomes more common, it is imperative
that radiologists and treating physicians are aware of
CARCs and their temporal evolution.
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